Please check your internet connection and try again.
# Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252520at
## Overview
Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252520at (milrinone) is a phosphodiesterase-3 inhibitor with positive inotropic and vasodilatory effects.
## Primary Indications
* Short-term management of acute decompensated heart failure.
* Bridge to cardiac transplantation in patients with severe heart failure.
## Adult Dosing
* **Loading Dose:** 50 mcg/kg administered intravenously over 10 minutes.
* **Maintenance Infusion:** 0.375 to 0.75 mcg/kg/min. The maximum recommended maintenance infusion rate is 0.75 mcg/kg/min.
## Pediatric Dosing
The use of milrinone in pediatric patients is generally off-label and dosing is highly individualized based on clinical status and institutional protocols. A common starting dose range is 0.125 to 0.75 mcg/kg/min after a loading dose, but precise guidelines are not universally established.
## Dose Adjustments
* **Renal Impairment:** If creatinine clearance is less than 30 mL/min/1.73 m², consider reducing the maintenance infusion rate by up to 50%. Milrinone is removed by dialysis, and dose should be reinitiated after dialysis.
## Contraindications
* Severe aortic stenosis or other obstructive aortic disease.
* Known hypersensitivity to milrinone.
## Adverse Effects
* Hypotension (most common).
* Arrhythmias (including ventricular tachycardia, premature ventricular contractions).
* Headache.
* Thrombocytopenia.
* Dizziness.
* Nausea.
## Key Drug Interactions
* **Furosemide:** Do not mix furosemide and milrinone in the same IV line, as it can cause precipitation. Administer via separate IV lines.
* **Other Inotropes:** Use with caution in combination with other inotropic agents.
## Monitoring
* Hemodynamic parameters (blood pressure, heart rate, cardiac output).
* Renal function.
* Platelet count.
* Signs of fluid overload.
## Clinical Pearls
* Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252520at is intended for short-term use. Prolonged use has been associated with increased mortality.
* Monitor blood pressure closely during infusion. If hypotension occurs, reduce the infusion rate.
* Discontinuation should be gradual to avoid potential hemodynamic deterioration.
---
**Disclaimer:** This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information and current clinical guidelines. Always verify the most up-to-date dosing and safety information before prescribing.
